24.08.2012 - The US government will support Novozymes's partner Chemtex Inc. in its aim to construct a cellulosic ethanol plant in North Carolina by backing a US$99m loan.
The plant is expected to be located in Sampson County, North Carolina and produce 20 million gallons (76 million liters) of bioethanol per year from up to 600,000 tons of non-food grasses. The enzymes necessary for processing the biomass will be provided by Danish biotech company Novozymes (Baegsvaard). The construction is set to begin in late 2012. “Realising a commercial scale cellulosic ethanol plant in the United States and proving that it can produce cost competitive sustainable ethanol is an important milestone in the commercialisation process of advanced biofuels,” said Guido Ghisolfi, President of the Chemtex Group, which is a unit of the Italian chemical company Grupo Mossi & Ghisolfi.http://www.gruppomg.com/history.php?mi=201
Slated to open in 2014, the plant will employ approximately 65 employees and indirectly generate 250 more jobs in the community, not including construction jobs. The feedstock will be grown on low productivity/marginal land that is in part being utilised as “spray fields” for the hog farming industry. Wilmington, North Carolina-based Chemtex received US$3.9m from the US Department of Agriculture in Junehttp://www.chemtex.com/templates/news_20120613.html to grow more than 4,000 acres of miscanthus and switchgrass, which will now be used as feedstock. Chemtex and Novozymes have already started a collaboration this April aimed at building the world’s first industrial plant for fermentation of second generation bioethanol from cheap straw feeds.
25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.